Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 5, keine Gesamtzahl für „substrate“
Suchtreffer
Begriffe & Kennungen
Brilique · 4.5 · There was no effect of ticagrelor on cyclosporine blood levels. Effect of ticagrelor on other P-gp substrates
Eintrag öffnenBrilique · 4.5 · Ticagrelor is a mild CYP3A4 inhibitor. Co-administration of ticagrelor and CYP3A4 substrates with narrow thera
Eintrag öffnenBrilique · 4.5 · Ticagrelor is a mild CYP3A4 inhibitor. Co-administration of ticagrelor and CYP3A4 substrates with narrow thera
Eintrag öffnenBrilique · 4.5 · Ticagrelor is a mild CYP3A4 inhibitor. Co-administration of ticagrelor and CYP3A4 substrates with narrow thera
Eintrag öffnenBrilique · 4.5 · Ticagrelor is primarily a CYP3A4 substrate and a mild inhibitor of CYP3A4. Ticagrelor is also a P-glycoprotein
Eintrag öffnenBrilique · 4.5 · Ticagrelor is primarily a CYP3A4 substrate and a mild inhibitor of CYP3A4. Ticagrelor is also a P-glycoprotein
Eintrag öffnenBrilique · 4.5 · Ticagrelor is primarily a CYP3A4 substrate and a mild inhibitor of CYP3A4. Ticagrelor is also a P-glycoprotein
Eintrag öffnenBrinavess · 4.5 · Although vernakalant is a substrate of CYP2D6, population pharmacokinetic (PK) analyses demonstrated that no s
Eintrag öffnenBrintellix · 4.5 · Cytochrome P450 substrates In vitro, vortioxetine did not show any relevant potential for inhibition or induct
Eintrag öffnenBrukinsa · 4.5 · 33 The coadministration of oral P-gp substrates with a narrow therapeutic index (e.g., digoxin) should be done
Eintrag öffnenBrukinsa · 4.5 · CYP2C19 substrates
Eintrag öffnenBrukinsa · 4.5 · CYP2C19 substrates
Eintrag öffnenBrukinsa · 4.5 · CYP3A substrates
Eintrag öffnenBrukinsa · 4.5 · CYP3A substrates
Eintrag öffnenBrukinsa · 4.5 · Co-administration of multiple doses of zanubrutinib decreased midazolam (CYP3A substrate) Cmax by 30% and AUC
Eintrag öffnenBrukinsa · 4.5 · Co-administration of multiple doses of zanubrutinib decreased midazolam (CYP3A substrate) Cmax by 30% and AUC
Eintrag öffnenBrukinsa · 4.5 · Co-administration of multiple doses of zanubrutinib decreased omeprazole (CYP2C19 substrate) Cmax by 20% and A
Eintrag öffnenBrukinsa · 4.5 · Co-administration of multiple doses of zanubrutinib decreased omeprazole (CYP2C19 substrate) Cmax by 20% and A
Eintrag öffnenBrukinsa · 4.5 · Co-administration of multiple doses of zanubrutinib increased digoxin (P-gp substrate) Cmax by 34% and AUC by
Eintrag öffnenBrukinsa · 4.5 · Co-administration of multiple doses of zanubrutinib increased digoxin (P-gp substrate) Cmax by 34% and AUC by
Eintrag öffnen